Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia

Leukemia

Volumn 10, Issue 4, 1996, Pages 675-681

  Kaspers, G J L ^a   Veerman, A J P ^a,b   Van Wering, E R ^b   Van Der Linden Schrever, B E M ^b   Van Zantwijk, C H ^a   Van Der Does Van Den Berg, A ^b   Pieters, R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

Childhood; Drug resistance; Glucocorticoids; Lectins; Leukemia; Prognosis

Indexed keywords

4 HYDROPEROXYIFOSFAMIDE; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PEANUT AGGLUTININ; PREDNISOLONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B CELL LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 0029927850     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. London J, Berrih S, Bach J-F. Peanut agglutinin. I. A new tool for studying T lymphocyte subpopulations. J Immunol 1978; 121: 438-443.
2. Reisner Y, Linker-Israeli M, Sharon N. Separation of mouse thymocytes into two subpopulations by the use of peanut agglutinin. Cell Immunol 1976; 25: 129-134.
3. Barzilay M, Rosenthal E, Kende G, Reisner Y, Sharon N, Ramot B. Binding of peanut agglutinin to normal human lymphocytes and to leukemic cells. Leuk Res 1982; 6: 123-125.
4. Dowell BL, Borowitz MJ, Boyett JM, Pullen DJ, Crist WM, Quddus FF, Russell EC, Falletta JM, Metzgar RS. Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. Cancer 1987; 59: 2020-2026.
5. Haar JL, Raynor RH, Russell EC, Bhatnagar AS, Mohanakumar T. Ultrastructural analysis of acute lymphoblastic cells: peanut lectin binding correlates with degree of differentiation of the leukemic cells. Exp Hematol 1985; 13: 169-173.
6. Levin S, Russell EC, Blanchard D, McWilliams NB, Maurer HM, Mohanakumar T. Receptors for peanut agglutinin (Arachus hypogea) in childhood acute lymphoblastic leukemia: possible clinical significance. Blood 1980; 55: 37-39.
7. Newman RA, Delia D. Analysis of the binding of peanut agglutinin (PNA) to leukaemic cells and its relationship to T-cell differentiation. Immunology 1983; 49: 147-152.
8. Richard Y, Boumsell L, Lemerle J, Valensi F, Bernard A. Probing human malignant T cells with lectins: a comparison with their surface antigen patterns defined by monoclonal antibodies. Leuk Res 1982; 6: 307-312.
9. Veerman AJP, Hogeman PHG, Huismans DR, Van Zantwijk CH, Bezemer PD. Peanut agglutinin, a marker for T-cell acute lymphoblastic leukemia with a good prognosis. Cancer Res 1985; 45: 1890-1893.
10. Weinberg DS, Ault KA, Pinkus GS. Circulating malignant cells in non-Hodgkin's lymphoma: correlation with binding by peanut agglutinin. Blood 1988; 72: 698-704.
11. 3 and glucocorticoids in the rat thymus gland. Endocrinology 1989; 124: 1532-1538.
12. Ranelletti FO, Pintelli M, Iacobelli S, Musiani P, Longo P, Lauriola L, Marchetti P. Glucocorticoid receptors and in vitro corticosensitivity of peanut-positive and peanut-negative human thymocyte subpopulations. J Immunol 1981; 127: 849-855.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981; 47: 553-561.
14. Van Wering ER, Brederoo P, Van Staalduinen CJ, Van Der Meulen J, Van Der Linden-Schrever BEM, Van Dongen JJM. Contribution of electron microscopy to the classification of minimally differentiated acute leukemias in children. Recent Results Cancer Res 1993; 131: 77-87.
15. Pieters R, Loonen AH, Huismans DR, Broekema CJ, Dirven MWJ, Heyenbrok MW, Hählen K, Veerman AJP. In vitro sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-2336.
16. Pieters R, Huismans DR, Leyva A, Veerman AJP. Adaptation of the rapid automated tetrazolium dye based MTT assay for chemosensitivity testing in childhood leukemia. Cancer Lett 1988; 41: 323-332.
17. Kaspers CJL, Pieters R, Van Zantwijk CH, De Laat PAJM, De Waal FC, Van Wering ER, Veerman AJP. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991; 64: 469-474.
18. Riehm H, Feickert H-J, Schrappe M, Henze C, Schellong G. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Transfus 1987; 30: 139-146.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Cox DR. Regression models and life tables. J R Stat Soc 1972, 34: 187-220.
21. Pieters R, Kaspers GJL, Van Wering ER, Huismans DR, Loonen AH, Hahlen K, Veerman AJP. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392-397.
22. Riehm H, Reiter A, Schrappe M, Berthold F, Dopier R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G. Die Corticosteroid-Abhangige Dezimierung der Leukamiezellzahl im Blut als Prognosefaktor bei der Akuten Lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Padiatr 1986, 199: 151-160.
23. Pieters R, Huismans DR, Loonen AH, Hählen K, Van Der Does-Van Den Berg A, Van Wering ER, Veerman AJP. Relation of cellular drug resistance to longterm clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338. 399-403.
24. Kaspers GJL, R Pieters, Van Zantwijk CH, ER Van Wering, A Van Der Does-Van Den Berg, AJP Veerman. Resistance to prednisolone (PRD) in vitro: a new prognostic factor in childhood acute lymphoblastic leukemia (ALL) at initial diagnosis. Proc Am Soc Clin Oncol 1993; 12: 320 (abstr.)
25. Kaspers GJL, Pieters R, Van Zantwijk CH, De Waal FC, Van Wering ER, Veerman AJP. Is resistance to prednisolone in vitro related to the response to prednisolone at initial diagnosis in childhood acute lymphoblastic leukemia? A preliminary analysis. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (eds). Drug Resistance in Leukemia and Lymphoma. The Clinical Value of Laboratory Assays. Harwood Academic: Chur. 1993, pp 321-328.
26. Veerman AJP, Pieters R. Drug sensitivity assays in leukaemia and lymphoma. Br J Haematol 1990; 74: 381-384.
27. Hongo T, Fujii Y, Igarashi Y. An in vitro chemosensitivity test for ,: the screening of anticancer drugs in childhood leukemia. Cancer 1990; 65: 1263-1272.
28. Nygren P, Kristensen J, Jonsson B, Sundstrom C, Lonnerholm G, Kreuger A, Larsson R. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992; 6: 1121-1128.
29. Bleyer WA, Dedrick RL. Clinical pharmacology of intra-thecal methotrexate: I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 1977; 61: 703-708.
30. Jacobs SA, Bleyer WA, Chabner BA, Johns DC. Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet 1975; 1: 465-466.
31. Thyss A, Munzer C, Mechinaud-Lacroix F, Boutard P, Suciu S, Solbu G, Tokaji E, Philippe N, Orten J for the EORTC CLCG. Intrathecal methotrexate (it MTX) is an important factor of the response to the so-called 'corticoid prephase' of the BFM protocol for ALL in the EORTC 58 881 trial Med Pediatr Oncol 1993; 21: 539 (abstr.).
32. Simmons ED, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 1991; 67: 2062-2065.
33. Cohen JJ. Lymphocyte death induced by glucocorticoids. In: Schleimer RP, Claman HN, Oronsky AL (eds). Anti-inflammatory Steroid Action. Basic and Clinical Aspects. Academic Press: San Diego, CA, 1989, pp 111-131.